PE20090214A1 - Perfil de temperatura de dos etapas para la propagacion de los virus - Google Patents

Perfil de temperatura de dos etapas para la propagacion de los virus

Info

Publication number
PE20090214A1
PE20090214A1 PE2008000784A PE2008000784A PE20090214A1 PE 20090214 A1 PE20090214 A1 PE 20090214A1 PE 2008000784 A PE2008000784 A PE 2008000784A PE 2008000784 A PE2008000784 A PE 2008000784A PE 20090214 A1 PE20090214 A1 PE 20090214A1
Authority
PE
Peru
Prior art keywords
virus
cell
cells
temperature profile
stage temperature
Prior art date
Application number
PE2008000784A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of PE20090214A1 publication Critical patent/PE20090214A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PRODUCCION DE UN VIRUS, PARTICULARMENTE DE Orthomyxovirus, Alfavirus o Flavivirus, QUE COMPRENDE DE: a)PROPORCIONAR UNA CELULA HUESPED, PROCEDENTE DE UN CULTIVO DE CELULAS DE ANIMAL O UNA LINEA CELULAR, TAL COMO CELULAS EPITELIALES, DE RINON O CELULAS VERO (celulas provenientes de rinon de monos), QUE HA SIDO INFECTADA; b)CULTIVAR DICHA CELULA A 31-37ºC DURANTE 1 A 48 hrs; c)CULTIVO DE LA CELULA HUESPED A 1-6ºC MENOS QUE LA PRIMERA TEMPERATURA; d)RECOLECTAR COPIAS DEL VIRUS PRODUCIDO MEDIANTE LAS ETAPAS DE CULTIVO. DICHOS VIRUS TAMBIEN SON DENOMINADOS VIRUS INFLUENZA, VIRUS ROSS RIVER Y VIRUS WEST NILE. SE REFIERE TAMBIEN A LA PREPARACION DE UNA VACUNA
PE2008000784A 2007-05-04 2008-05-05 Perfil de temperatura de dos etapas para la propagacion de los virus PE20090214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92769307P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
PE20090214A1 true PE20090214A1 (es) 2009-03-20

Family

ID=39670405

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000784A PE20090214A1 (es) 2007-05-04 2008-05-05 Perfil de temperatura de dos etapas para la propagacion de los virus

Country Status (19)

Country Link
US (2) US8426124B2 (es)
EP (1) EP2155863B1 (es)
JP (2) JP5352578B2 (es)
KR (1) KR101581228B1 (es)
CN (2) CN101688186A (es)
AR (1) AR066450A1 (es)
AU (1) AU2008248905B2 (es)
BR (1) BRPI0811533A2 (es)
CA (1) CA2687122C (es)
CL (1) CL2008001295A1 (es)
ES (1) ES2521496T3 (es)
HK (2) HK1137780A1 (es)
IL (1) IL201896A (es)
MX (1) MX2009011899A (es)
PE (1) PE20090214A1 (es)
RU (1) RU2476594C2 (es)
TW (1) TWI447226B (es)
WO (1) WO2008135230A1 (es)
ZA (1) ZA200907744B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914163B1 (fr) * 2007-04-02 2009-06-05 Oreal Applicateur pour appliquer une composition sur les cils
US9555067B2 (en) 2012-04-18 2017-01-31 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1526172A1 (de) * 1965-04-22 1969-07-31 Steinmueller Gmbh L & C Aus mehreren Stufen aufgebauter Regenerativ-Waermeaustauscher
US4301250A (en) * 1979-11-02 1981-11-17 Merck & Co., Inc. Method of producing hepatitis B surface antigen
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
RU2181295C1 (ru) * 2000-12-27 2002-04-20 Научно-исследовательский институт вирусологии им. Д.И. Ивановского РАМН (учреждение) Вирионная цитомегаловирусная вакцина и способ ее получения
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
ES2299715T3 (es) * 2002-03-29 2008-06-01 MERCK & CO., INC. Procedimientos de produccion de virus.
CA2523319A1 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
DK2368975T3 (en) * 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses

Also Published As

Publication number Publication date
JP5978172B2 (ja) 2016-08-24
MX2009011899A (es) 2010-03-30
KR101581228B1 (ko) 2015-12-30
CL2008001295A1 (es) 2009-06-26
US8426124B2 (en) 2013-04-23
RU2009144970A (ru) 2011-06-10
IL201896A0 (en) 2011-08-01
IL201896A (en) 2013-08-29
JP2013198502A (ja) 2013-10-03
HK1216104A1 (zh) 2016-10-14
TW200914616A (en) 2009-04-01
CA2687122C (en) 2017-06-13
BRPI0811533A2 (pt) 2014-10-14
EP2155863A1 (en) 2010-02-24
JP2010525799A (ja) 2010-07-29
EP2155863B1 (en) 2014-08-13
CN104962525A (zh) 2015-10-07
AU2008248905A1 (en) 2008-11-13
CN101688186A (zh) 2010-03-31
WO2008135230A1 (en) 2008-11-13
RU2476594C2 (ru) 2013-02-27
HK1137780A1 (en) 2010-08-06
KR20100017593A (ko) 2010-02-16
ZA200907744B (en) 2010-08-25
TWI447226B (zh) 2014-08-01
CA2687122A1 (en) 2008-11-13
ES2521496T3 (es) 2014-11-12
JP5352578B2 (ja) 2013-11-27
AU2008248905B2 (en) 2014-05-29
US20080286307A1 (en) 2008-11-20
AR066450A1 (es) 2009-08-19
US20100239606A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
BR112022015053A2 (pt) Composições imunizantes contra vírus respiratórios
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
UY34983A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CO6761348A2 (es) Compuestos antivirales
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CO6511251A2 (es) Compuestos quimicos
UY32759A (es) Inhibidores del virus de la hepatitis c
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CR20110605A (es) Compuestos heterocíclicos antivirales
EA201390810A1 (ru) Жидкие вирусные составы
EA201000277A1 (ru) Соединения для лечения гепатита с
EA201390812A1 (ru) Лиофилизированные вирусные составы
BR112014013972A2 (pt) inibidores de hcv nssa
BR112015007879A2 (pt) inibidores do vírus da hepatite c
ES2585242T3 (es) Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
AR072976A1 (es) Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112014015582A8 (pt) compostos antivirais
GT201100241A (es) Proceso para preparar compuestos antivirales
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
EA201270798A1 (ru) Соединения для лечения гепатита с

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed